Real-world analysis of cost, treatment patterns, and outcomes of patients with metastatic cutaneous squamous cell carcinoma in the US
Expert Review of Pharmacoeconomics & Outcomes Research · 2023
DOI: 10.1080/14737167.2023.2223982 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2023. Verfasst von Xue Song und 4 weiteren Autor:innen. Beteiligte Einrichtung: Regeneron Pharmaceuticals, Inc, Sleepy Hollow, NY, USA. Hauptthemen laut MEDLINE: Carcinoma, Squamous Cell, Skin Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Regeneron Pharmaceuticals, Sanofi.
Abstract (Originalsprache)
OBJECTIVES: To describe real-world characteristics and treatment patterns of patients with metastatic cutaneous squamous cell carcinoma (mCSCC). METHODS: This retrospective observational study used MarketScan Commercial and Medicare Supplemental claims databases (1/1/2013-7/31/2019). Adult patients with mCSCC who initiated non-immunotherapy systemic treatment (i.e. index event) between 1 January 2014 and 31 December 2018 were assessed for treatment patterns, all-cause and CSCC-related healthcare resource utilization, costs, and mortality . RESULTS: Overall, 207 patients were included in the study(mean age 64.8 years, 76.3% male), 59.4% had prior radiotherapy, and 58.9% had prior CSCC-related surgery. During follow-up, 75.8%, 51.7%, and 35.7% of patients received chemotherapy, radiotherapy, and targeted therapy as first-line treatment, respectively. Cisplatin (32.9%) and carboplatin (22.7%) were the most common chemotherapy agents, and cetuximab (32.4%) was the most common targeted therapy during the first-line.Probability of death (95% CI) at month 6, year 1, and year 2 was 24% (16-32%), 50% (40 - 59%), and 67% (56 - 75%), respectively. Average CSCC-related healthcare costs were $5,354 per person per month (PPPM), with outpatient costs being the major cost driver at 96.4% ($5,160 PPPM). CONCLUSION: During 2014-2018, patients with mCSCC were commonly treated with cisplatin and cetuximab; prognosis was generally poor. These results indicate opportunity for new treatments to improve survival outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Regeneron Pharmaceuticals, Inc, Sleepy Hollow, NY, USA.
- Sanofi, Reading, UK.
- Outcomes Research, IBM Watson Health, Cambridge, MA, USA.
- Department of Dermatology, Dana-Farber Cancer Institute, Boston, MA, USA.
Förderung
- Regeneron Pharmaceuticals
- Sanofi
Zitieren
APA
Song, X., Chen, C. I., Konidaris, G., Zimmerman, N. M., & Ruiz, E. (2023). Real-world analysis of cost, treatment patterns, and outcomes of patients with metastatic cutaneous squamous cell carcinoma in the US. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2023.2223982
Vancouver
Song X, Chen CI, Konidaris G, Zimmerman NM, Ruiz E. Real-world analysis of cost, treatment patterns, and outcomes of patients with metastatic cutaneous squamous cell carcinoma in the US. Expert Review of Pharmacoeconomics & Outcomes Research. 2023. doi:10.1080/14737167.2023.2223982
BibTeX
@article{Song2023,
author = {Song, Xue and Chen, Chieh-I and Konidaris, Gerasimos and Zimmerman, Nicole M and Ruiz, Emily},
title = {Real-world analysis of cost, treatment patterns, and outcomes of patients with metastatic cutaneous squamous cell carcinoma in the US},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2023},
doi = {10.1080/14737167.2023.2223982}
}
EUVIMED